1. Home
  2. GNK vs GERN Comparison

GNK vs GERN Comparison

Compare GNK & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genco Shipping & Trading Limited New (Marshall Islands)

GNK

Genco Shipping & Trading Limited New (Marshall Islands)

HOLD

Current Price

$24.05

Market Cap

967.7M

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.26

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNK
GERN
Founded
2004
1990
Country
United States
United States
Employees
N/A
258
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
967.7M
808.3M
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
GNK
GERN
Price
$24.05
$1.26
Analyst Decision
Buy
Hold
Analyst Count
2
3
Target Price
$19.00
$2.17
AVG Volume (30 Days)
347.4K
13.9M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
3.90%
N/A
EPS Growth
N/A
N/A
EPS
0.21
N/A
Revenue
$342,054,000.00
N/A
Revenue This Year
$21.15
$26.91
Revenue Next Year
$1.41
$43.75
P/E Ratio
$114.52
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.66
$1.04
52 Week High
$27.25
$2.01

Technical Indicators

Market Signals
Indicator
GNK
GERN
Relative Strength Index (RSI) 48.35 34.40
Support Level $22.40 $1.22
Resistance Level $24.25 $1.29
Average True Range (ATR) 0.86 0.06
MACD -0.18 -0.00
Stochastic Oscillator 17.64 21.15

Price Performance

Historical Comparison
GNK
GERN

About GNK Genco Shipping & Trading Limited New (Marshall Islands)

Genco Shipping & Trading Ltd is an international shipping company specializing in the transportation of iron ore, coal, grain, steel products and other drybulk cargoes. It is involved in the ocean transportation of drybulk cargoes. The company operates in one segment, with two reportable segment: Major and Minor bulk fleet. It generates revenue through time charter agreements, spot market voyage charters, pool agreements and spot market-related time charters. oyage revenues also include the sale of bunkers consumed during short-term time charters pursuant to the terms of the time charter agreement.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: